All In Biotech

Drug Trial Radar · NCT07322016

A Study of HRS-1301 Tablets in Healthy Subjects and Those With Impaired Kidney Function

A Single-dose, Open-label Phase I Clinical Trial Comparing the Pharmacokinetics, Safety and Pharmacodynamics of HRS-1301 Tablets in Subjects With Mild, Moderate and Severe Renal Insufficiency and Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Jan 13, 2026

Primary completion

Aug 4, 2026

Study completion Aug 4, 2026

Sponsor

Sponsor type
Industry
First posted
Jan 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate pharmacokinetics of HRS-1301 tablets in subjects with impaired kidney function in comparison with healthy subjects, to develop dose recommendations for patients with renal impairment.

Conditions

  • Hyperlipidemias

Interventions

  • HRS-1301 TabletDrug

    HRS-1301 tablet, oral medication.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum concentration (Cmax).Time frame: 0 hour to 8 days after dosing.
  2. Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-last).Time frame: 0 hour to 8 days after dosing.
  3. Area under the concentration-time curve from time zero to infinity (AUC0-inf).Time frame: 0 hour to 8 days after dosing.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.